By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Portola Pharmaceuticals, Inc. 

270 East Grand Avenue

South San Francisco  California  94080  U.S.A.
Phone: 650-246-7000 Fax: 650-246-7376


Portola Pharmaceuticals, Inc. is a biopharmaceutical company that engages in the development and commercialization of novel therapeutics in the areas of thrombosis and other hematologic disorders and inflammation. Its development-stage portfolio consists of the compounds including Betrixaban, a novel oral once-daily inhibitor of Factor Xa in phase three clinical trials for extended duration prophylaxis, or preventive treatment of a form of thrombosis known as venous thromboembolism, in acute medically ill patients; Andexanet alfa, a recombinant protein designed to reverse anticoagulant activity in patients treated with a Factor Xa inhibitor; and Cerdulatinib, an orally available kinase inhibitor that inhibits spleen tyrosine kinase and janus kinases, enzymes that regulate important signaling pathways.


September 2, 2003


Founder: Charles Homcy and David Philips

CEO: William Lis

CFO: Mardi Dier

CTO: R. Andrew Ramelmeier


Please click here for Portola job opportunities.


Please click here for clinical trial information.


Key Statistics

Ownership: Public

Web Site: Portola
Employees: 130
Symbol: PTLA

Start Up

Company News
Portola (PTLA) Announces Pricing Of Public Offering Of Common Stock 9/13/2017 7:19:11 AM
Portola (PTLA) Announces Proposed Offering Of Common Stock 9/12/2017 8:42:02 AM
Reminder: Portola (PTLA) To Host Webcast And Conference Call Today, Tuesday, Sept. 5 To Provide Further Details On Bevyxxa (Betrixaban) Launch 9/5/2017 10:37:36 AM
Portola (PTLA) Announces Andexxa (Andexanet Alfa) Biologics License Application Resubmission Accepted For Review By U.S. FDA 8/15/2017 7:39:02 AM
Portola (PTLA) Reports Second Quarter 2017 Financial Results And Provides Corporate Update 8/10/2017 12:46:40 PM
Portola (PTLA) Announces Resubmission Of Biologics License Application For AndexXa (Andexanet Alfa) 8/4/2017 7:57:50 AM
Portola (PTLA) Reports Inducement Grants Under NASDAQ Listing Rule 5635(C)(4) 7/28/2017 10:30:56 AM
Bay Area's Portola (PTLA) Rockets as the FDA Approves First and Only Anticoagulant for Hospitals 6/26/2017 7:04:47 AM
Portola (PTLA) Presents Interim Phase IIa Safety And Efficacy Data For Cerdulatinib At The International Congress Of Malignant Lymphoma 6/15/2017 7:35:30 AM
Portola (PTLA) Reports First Quarter 2017 Financial Results And Provides Corporate Update 6/12/2017 3:16:56 PM